Current Status of Immunotherapy for Lung Cancer and Future Perspectives
김호철, 최창민,
소속 상세정보
김호철 ( Kim Ho-Cheol )
University of Ulsan College of Medicine Asan Medical Center Department of Pulmonary and Critical Care Medicine
최창민 ( Choi Chang-Min )
University of Ulsan College of Medicine Asan Medical Center Department of Pulmonary and Critical Care Medicine
Abstract
Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, new therapeutic strategies are needed to improve clinical outcomes. Immunotherapy through the use of immune checkpoint inhibitors has provided one of the most important breakthroughs in the management of solid tumors, including lung cancers, and has shown promising results in numerous clinical trials. This review will present the current status of immunotherapy for lung cancer and future perspectives on these treatments.
키워드
Lung Neoplasms; Immunotherapy; Prognosis; Survival
원문 및 링크아웃 정보
등재저널 정보